Millennium/Sanofi Discontinue Phase II CCR1 Inhibitor For Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
Candidate demonstrated safety but did not reach prespecified endpoint, Millennium CEO Dunsire says.
You may also be interested in...
Millennium Shops Atherosclerosis Candidate After Positive Phase II
Biopharma seeks a partner before bringing the CCR2 antagonist into Phase III, firm tells “The Pink Sheet” DAILY.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.